All In Biotech

NDA 207533 · Alkermes INC

Aristada

Aripiprazole Lauroxil · Intramuscular

Novel

Last checked: Nov 20, 2026Latest source record: Jan 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Oct 5, 2015

Approved uses

2

Original approval plus efficacy supplements

Registered trials

8

2 Phase 3, 0 recruiting

FAERS reports

4,559

789 serious, 81 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ARISTADA is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions ( 5.1 )] . WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ( 5.1 ) ARISTADA is not approved for the treatment of patients with dementia-related psychosis. ( 5.1 )

What it is approved for

From the label in effect Jan 28, 2025.

ARISTADA is indicated for the treatment of schizophrenia in adults [see Clinical Studies ( 14 )]. ARISTADA is an atypical antipsychotic indicated for the treatment of schizophrenia in adults ( 1 ).

Mechanism: Aripiprazole lauroxil is a prodrug of aripiprazole. Following intramuscular injection, aripiprazole lauroxil is likely converted by enzyme-mediated hydrolysis to N-hydroxymethyl aripiprazole, which is then hydrolyzed to aripiprazole. The mechanism of action of aripiprazole in schizophrenia is unknown. However, efficacy could be mediated through a combination of partial agonist activity at dopamine D 2 and serotonin 5-HT 1A receptors and antagonist activity at 5-HT 2A receptors.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • ARISTADA · ARIPIPRAZOLE LAUROXIL 1064MG/3.9ML (272.82MG/ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
  • ARISTADA · ARIPIPRAZOLE LAUROXIL 662MG/2.4ML (275.83MG/ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
  • ARISTADA · ARIPIPRAZOLE LAUROXIL 882MG/3.2ML (275.63MG/ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
  • ARISTADA · ARIPIPRAZOLE LAUROXIL 441MG/1.6ML (275.63MG/ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Aripiprazole Lauroxil" as an intervention, any sponsor and status, largest first.

All 8 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use1,132
  • needle issue667
  • injection site pain434
  • drug ineffective271
  • product administered at inappropriate site218
  • weight increased218
  • incorrect dose administered201
  • therapeutic response shortened182
  • hallucination, auditory175
  • syringe issue174
  • underdose169
  • anxiety156

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20152
2016300
2017580
2018867
2019515
2020423
2021397
2022359
2023376
2024275
2025242
2026223

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Aristada (Aripiprazole Lauroxil)

2024 spending

$269M

Beneficiaries

13,102

90,057 claims

Per beneficiary

$20,537

$976.79 per unit

View as table
YearSpending
2020$203,135,527
2021$230,380,653
2022$256,918,832
2023$272,878,291
2024$269,076,005

Part B: Aristada (Aripiprazole Lauroxil) · HCPCS J1944

2024 spending

$1.5M

Beneficiaries

211

992 claims

Per beneficiary

$7,183

2024 ASP limit $3.17 per unit

View as table
YearSpending
2020$845,101
2021$1,076,316
2022$1,357,076
2023$1,424,750
2024$1,515,511

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 23 on PubMed

Sponsor: Alkermes INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.